Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is ...
'My liver had turned into a tumour-making machine'
I wasn't ill apart from some tiredness.” After being on the organ donor waiting list for four months, Mandy was matched with a unique patient – a donor who had received a liver just three weeks prior ...
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
Crime14d
'My liver had turned into a tumour-making machine'
And there was.” Mandy, from Newcastle-under-Lyme in Staffordshire, was diagnosed with primary biliary cholangitis (PBC), a liver disease which causes liver failure. The condition also leaves ...
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
PMLiVE23d
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...